Abstract PD6-09: The immune microenvironment in hormone receptor-positive breast cancer patients and relationship to treatment outcome following preoperative chemotherapy plus bevacizumab
Waks, AG, Stover, DG, Barry, W, Dillon, D, Gjini, E, Rodig, SJ, Brock, J, Baltay, M, Savoie, J, Winer, EP, Krop, I, Tolaney, SM
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Get full text
Journal Article
Abstract P3-07-31: Immune activation signatures identify a subset of ER+ breast cancers with increased pathologic complete response to neoadjuvant chemotherapy
Stover, DG, Waks, AG, Erica, ML, Brugge, JS, Winer, EP, Selfors, LM
Published in Cancer research (Chicago, Ill.) (15.02.2016)
Published in Cancer research (Chicago, Ill.) (15.02.2016)
Get full text
Journal Article
Abstract PD5-06: Adjuvant palbociclib plus endocrine therapy for hormone receptor positive/HER2 negative breast cancer: A phase II feasibility study
Mayer, EL, DeMichele, AM, Guo, H, Miller, KD, Rugo, HS, Schneider, B, Waks, AG, Come, SE, Mulvey, T, Huang Bartlett, C, Koehler, M, Barry, W, Winer, EP, Burstein, HJ
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Get full text
Journal Article